Investment Portfolio - As of December 31, 2023, the group held several investment and financial products valued at 5% or more of the total assets, including New China Innovation Fund with an investment cost of $15 million and unrealized gains of RMB 108,437 thousand, representing 6.44% of total assets [2]. - The group also invested $14.5 million in IndexCap Med&Tech I L.P., with unrealized gains of RMB 103,058 thousand, accounting for 24.81% of total assets [3]. - There were no other significant investments disclosed during the reporting period, maintaining consistency with the 2023 annual report [4]. Investment Strategy - No realized gains or dividends were recorded from the investment and financial products during the reporting period, indicating a cautious investment strategy [3]. - The group plans to hold these investments as needed to generate stable income, closely monitoring market changes [3].
鹰瞳科技-B(02251) - 2024 - 年度业绩